Acrivon Therapeutics: Priced For Failure, Built For Precision

Acrivon Therapeutics (ACRV) trades below cash value, with the market deeply discounting its platform and pipeline despite promising early data. ACRV's AP3 platform enables precision patient-matching for kinase inhibitor therapies, showing a 50% response rate in serous endometrial cancer with ACR-368. Key near-term catalysts include Phase 2b ACR-368 data and Phase 1 ACR-2316 expansion results, both critical for de-risking and expanding commercial potential. RA Capital increased its stake to 28% at $1.80/share, signaling conviction amid market skepticism, high cash burn, and patent headwinds.

Acrivon Therapeutics ( ACRV ) is a clinical-stage biotechnology company with a proprietary, patient-matching, approach, which they term AP3 (Acrivon Predictive Precision Proteomics) to identify cancer patients that will most likely benefit from any particular drug.